Aragen Bioscience

ANTIBODY DISCOVERY

Experts in antigen design and hybridoma development.

In-depth experience from gene synthesis and subcloning to protein expression and purification.

Proven track record for a broad range of in vitro and in vivo models of disease.

Short timelines and high titers at every development stage with RapTr^™ CLD services.

Relive our June 20th webinar! Instant Replay

May 22-23
Boston, MA

May 23
San Diego, CA

June 3-6
Philadelphia, PA

Booth 3513

…a solid performer for my company’s animal studies…
Elisabeth Gardiner, PhD Chief Scientific Officer Meditope Biosciences, Inc.

GVK BIO announces the appointment of Axel Schleyer, Ph.D. as Chief Executive Officer, Aragen Bioscience, Inc.

Aragen Bioscience Expands RapTr Cell Line Development Services

11.10.2017
Aragen Bioscience Announces AAALAC Accreditation

06.20.2017
RapTr Cell Line Development Services Introduced